MA35419B1 - Inhibiteurs de la tyrosine kinase de bruton - Google Patents

Inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
MA35419B1
MA35419B1 MA36783A MA36783A MA35419B1 MA 35419 B1 MA35419 B1 MA 35419B1 MA 36783 A MA36783 A MA 36783A MA 36783 A MA36783 A MA 36783A MA 35419 B1 MA35419 B1 MA 35419B1
Authority
MA
Morocco
Prior art keywords
compounds
inhibitors
tyrosine kinase
diseases associated
present
Prior art date
Application number
MA36783A
Other languages
English (en)
Inventor
Christine Brotherton-Pleiss
Saul Jaime-Figueroa
Francisco Javier Lopez-Tapia
Yan Lou
Timothy D Owens
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35419B1 publication Critical patent/MA35419B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés selon la formule générique i : dans laquelle les variables sont telles que définies dans la description, et qui inhibent btk. Les composés décrits présentement sont utiles pour moduler l'activité de btk et traiter des maladies associées à une activité btk excessive. Les composés sont en outre utiles pour traiter des maladies inflammatoires et auto-immunes associées à une prolifération aberrante de lymphocytes b, telles que la polyarthrite rhumatoïde. La présente invention concerne en outre des compositions contenant des composés de formule i et au moins un véhicule, diluant ou excipient.
MA36783A 2011-08-17 2014-02-26 Inhibiteurs de la tyrosine kinase de bruton MA35419B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524374P 2011-08-17 2011-08-17
US201261649991P 2012-05-22 2012-05-22
PCT/EP2012/065844 WO2013024078A1 (fr) 2011-08-17 2012-08-14 Inhibiteurs de la tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA35419B1 true MA35419B1 (fr) 2014-09-01

Family

ID=46690498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36783A MA35419B1 (fr) 2011-08-17 2014-02-26 Inhibiteurs de la tyrosine kinase de bruton

Country Status (22)

Country Link
US (1) US8889682B2 (fr)
EP (1) EP2744804B1 (fr)
JP (1) JP5823616B2 (fr)
KR (1) KR20140052032A (fr)
CN (1) CN103748088A (fr)
AR (1) AR087543A1 (fr)
AU (1) AU2012296888A1 (fr)
BR (1) BR112014003582A2 (fr)
CA (1) CA2841801A1 (fr)
CL (1) CL2014000350A1 (fr)
CO (1) CO6842020A2 (fr)
CR (1) CR20140027A (fr)
EA (1) EA024689B1 (fr)
EC (1) ECSP14013212A (fr)
HK (1) HK1197060A1 (fr)
IL (1) IL230561A0 (fr)
MA (1) MA35419B1 (fr)
MX (1) MX349372B (fr)
PE (1) PE20140865A1 (fr)
TW (1) TW201311669A (fr)
WO (1) WO2013024078A1 (fr)
ZA (1) ZA201400739B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
EA027561B1 (ru) 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
BR112014010460A2 (pt) 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2013157021A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales de ceux-ci
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
EP2877598A1 (fr) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associées à la résistance à des inhibiteurs de la tyrosine kinase de bruton (btk)
MX2015001802A (es) 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
US9458105B2 (en) * 2012-11-16 2016-10-04 Hoffmann-La Roche Inc. Inhibitors of Bruton's tyrosine kinase
BR112015010121A2 (pt) * 2012-11-30 2017-07-11 Hoffmann La Roche inibidores de quinase de tirosina de bruton
RU2618529C2 (ru) * 2013-03-05 2017-05-04 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CN110698481B (zh) * 2013-07-03 2023-02-28 豪夫迈·罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
EP3026050B1 (fr) 2013-07-26 2018-11-07 Carna Biosciences Inc. Nouveau dérivé triazine
US20160221991A1 (en) * 2013-09-20 2016-08-04 Carna Biosciences, Inc. Novel triazine derivative
CA2929918C (fr) 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Composes de pyridone heteroarylique et d'aza-pyridone a fonctionnalite electrophile
EP3042903B1 (fr) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Composés hétéro-bicycliques substitués, compositions et leurs applications médicales
PT3247699T (pt) 2015-01-22 2019-08-06 Sanofi Aventis Deutschland Processo para a produção de 2-[4-(ciclopropanocarbonil)fenil]-2-metil-propanonitrilo
EP3365335B1 (fr) 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
EP4146639A1 (fr) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-hétéroaryloxy benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
EP4267574A1 (fr) 2020-12-23 2023-11-01 Ajax Therapeutics, Inc. 6-hétéroaryloxy benzimidazoles et azabenzimidazoles utilisés en tant qu'inhibiteurs de jak2
WO2023009709A1 (fr) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Pyrazolo pipérazines en tant qu'inhibiteurs de jak2
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
CN115073299B (zh) * 2022-06-14 2024-06-25 爱斯特（成都）生物制药股份有限公司 一种制备2-氟-3-三氟甲基苯胺的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683064B2 (en) * 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
NZ586916A (en) * 2008-02-05 2012-06-29 Hoffmann La Roche Novel pyridinones and pyridazinones
CA2728016C (fr) * 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Nouvelles pyridine-2-ones et pyridazine-3-ones substituees
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
BR112014010460A2 (pt) * 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
EP2788020A4 (fr) * 2011-12-05 2015-04-29 Immunomedics Inc Utilisation thérapeutique d'anticorps anti-cd22 pour induire une trogocytose

Also Published As

Publication number Publication date
EP2744804B1 (fr) 2017-05-17
ECSP14013212A (es) 2014-03-31
HK1197060A1 (en) 2015-01-02
CN103748088A (zh) 2014-04-23
TW201311669A (zh) 2013-03-16
CR20140027A (es) 2014-03-13
CO6842020A2 (es) 2014-01-20
KR20140052032A (ko) 2014-05-02
US8889682B2 (en) 2014-11-18
MX2014001653A (es) 2014-03-21
EP2744804A1 (fr) 2014-06-25
JP2014521734A (ja) 2014-08-28
BR112014003582A2 (pt) 2017-03-14
JP5823616B2 (ja) 2015-11-25
ZA201400739B (en) 2016-01-27
EA024689B1 (ru) 2016-10-31
IL230561A0 (en) 2014-03-31
EA201490452A1 (ru) 2014-05-30
MX349372B (es) 2017-07-26
CA2841801A1 (fr) 2013-02-21
WO2013024078A1 (fr) 2013-02-21
CL2014000350A1 (es) 2014-08-22
PE20140865A1 (es) 2014-07-19
AU2012296888A1 (en) 2014-01-23
AR087543A1 (es) 2014-04-03
US20130045965A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA35112B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA34465B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA32064B1 (fr) Nouvelles pyridinones et pyridazinones
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
DE602004013563D1 (de) Rantagonisten
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA35153B1 (fr) Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants
MA31766B1 (fr) Composés organiques
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
WO2006029153A3 (fr) Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
DE602005020656D1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
WO2006031513A3 (fr) Antagonistes des recepteurs cgrp d'aryle-spirolactame